The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:
----------
Alliance Trust PLC - Dundee-headquartered global equities investor - Beats benchmark in half-year despite falling net asset value. Net asset value falls to 964.0 pence per share as at June 30 from 1064.6p a year ago. NAV total return is negative 10.5%, beating its benchmark’s negative 11.0% total return. Declares total dividend for half-year of 12.0p, up 62% from 7.404p a year ago. ‘Our diversified, high conviction approach protected shareholders from the worst of the first half falls, resulting in performance slightly ahead of our benchmark,’ says Chair Gregor Stewart. ‘While the outlook remains challenging, with pressures from inflation and global political risks, we expect the resilient companies identified by our stock pickers to prosper,’ firm adds.
----------
Oberon Investments Group PLC - London-based investment manager - Narrows annual loss as revenue jumps and it expects to meet growth expectations for financial year 2023. Pretax loss narrows to £580,814 from £894,178 a year ago. Revenue surges 75% to £6.7 million from £3.8 million. Expects to grow, as ‘the directors believe that the company is in a strong position to attract new clients and teams to the fund management business.’
----------
Greencare Capital PLC - invests in medicinal cannabis - Posts higher loss. Pretax loss in the half-year to April 30 widens to £258,000 from £102,000 a year ago. Records no revenue, unchanged from prior year. Maintains positive outlook for medical cannabis and sees itself ‘well-placed to deploy funds’ to benefit from evolving regulation.
----------
Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Revenue in year ended March 31 falls to £50,000 from £195,500. Pretax loss narrows to £1.3 million from £1.4 million. Administrative expenses cut to £1.3 million from £1.5 million. Meanwhile, announces that co-founder and former Chief Executive Officer Daniel Gooding is appointed as executive director from August 1. Further, firm promotes Non-Executive Director Julian Gilbert to chair. The firm has several cancer and fibrosis drug candidates in early-stage development.
----------
Copyright 2022 Alliance News Limited. All Rights Reserved.
